# Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

> **NCT05888103** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 207 (actual)

## Conditions studied

- Primary Hypercholesterolemia or Mixed Dyslipidemia

## Interventions

- **DRUG:** Inclisiran
- **DRUG:** Matching Placebo for Inclisiran

## Key facts

- **NCT ID:** NCT05888103
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-11
- **Primary completion:** 2024-04-02
- **Final completion:** 2024-10-24
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05888103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05888103, "Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05888103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*